Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CADL Candel Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CADL
Price (delayed)
$5.35
Market cap
$268.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.31
Enterprise value
$186.53M
Highlights
CADL's quick ratio has surged by 140% year-on-year and by 68% since the previous quarter
Candel Therapeutics's debt has decreased by 48% YoY and by 19% QoQ
The net income has grown by 28% since the previous quarter but it has declined by 6% year-on-year
Candel Therapeutics's EPS has increased by 25% QoQ but it has decreased by 2.3% YoY
Key stats
What are the main financial stats of CADL
Market
Valuations
Earnings
Shares outstanding
50.1M
Market cap
$268.05M
Enterprise value
$186.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$33.6M
Net income
-$39.58M
EBIT
-$37.83M
EBITDA
-$36.56M
Free cash flow
-$27.21M
Per share
Balance sheet
Liquidity
EPS
-$1.31
EPS diluted
-$1.33
Free cash flow per share
-$0.54
Book value per share
$1.58
Revenue per share
$0
TBVPS
$1.9
Total assets
$95.91M
Total liabilities
$21.23M
Debt
$10.91M
Equity
$74.68M
Working capital
$73.08M
Debt to equity
0.15
Current ratio
4.64
Quick ratio
4.61
Net debt/EBITDA
2.23
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-63.1%
Return on equity
-136.7%
Return on invested capital
N/A
Return on capital employed
-49.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CADL stock price
How has the Candel Therapeutics stock price performed over time
Intraday
4.7%
1 week
11.23%
1 month
18.1%
1 year
-57.87%
YTD
-38.36%
QTD
-5.31%
Financial performance
How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$33.6M
Net income
-$39.58M
Gross margin
N/A
Net margin
N/A
The net income has grown by 28% since the previous quarter but it has declined by 6% year-on-year
The company's operating income rose by 8% YoY
Price vs fundamentals
How does CADL's price correlate with its fundamentals
Growth
What is Candel Therapeutics's growth rate over time
Valuation
What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
3.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has increased by 25% QoQ but it has decreased by 2.3% YoY
Candel Therapeutics's equity has increased by 13% QoQ
Efficiency
How efficient is Candel Therapeutics business performance
Candel Therapeutics's ROE has soared by 71% from the previous quarter and by 34% YoY
CADL's ROA is up by 47% from the previous quarter and by 24% YoY
Dividends
What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CADL.
Financial health
How did Candel Therapeutics financials performed over time
CADL's quick ratio has surged by 140% year-on-year and by 68% since the previous quarter
The current ratio has soared by 132% YoY and by 68% from the previous quarter
Candel Therapeutics's debt is 85% lower than its equity
CADL's debt to equity has dropped by 96% year-on-year and by 25% since the previous quarter
Candel Therapeutics's debt has decreased by 48% YoY and by 19% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.